QS - Lloyds Banking Group Barclays leads premarket losers' pack

Nabriva Therapeutics NBRV -30% after priced $15M public offering.Aytu BioScience (AYTU) -25% on raising 'bought deal' offering to $25M.Immutep (IMMP) -24%.Professional Diversity Network (IPDN) -24%.SELLAS Life Sciences Group SLS -21% after announcing positive follow-up data from Phase 2 VADIS trial of Nelipepimut-S in women with ductal carcinoma in-situ of the breast.Amplify Energy AMPY -18% on news that shareholders affiliated with Fir Tree Capital are launching a public offering of more than 8.5M common shares.Greenwich LifeSciences GLSI -17% on presenting GP2 late-stage study design for recurring breast cancer.Innate Pharma IPHA -16% after announcing that it will return the U.S. and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca.Panbela Therapeutics (PBLA) -16%.UTStarcom Holdings (UTSI) -12%.Option Care Health OPCH -11% under pressure on 10M shares secondary offering.Blonder Tongue Laboratories BDR -11% on receipt of noncompliance notice from NYSE.Regulus Therapeutics (RGLS) -9%.NatWest Group (NWG) -9%.Midatech Pharma (MTP) -9% on launch of new website.Phio Pharmaceuticals (PHIO) -8%.DBV Technologies (DBVT) -8%.Lloyds Banking Group (LYG) -8%.GeoVax Labs (GOVX) -8%.CureVac (CVAC) -7%.QuantumScape (QS) -6%.Luminar LAZR -6% after rival Innoviz announces

For further details see:

Lloyds Banking Group, Barclays leads premarket losers' pack